6,10 At baseline, 97% were treated with one or more glucose-lowering medications: metformin (76%), insulin (51%), SGLT-2 inhibitor (27%), sulfonylurea (29%), and DPP-4 inhibitors (23%)
Since the cellular synthesis of glutathione is ATP-dependent, decreased ETC activity also undermines glutathione synthesis, further exacerbating oxidative stress in a vicious cycle [8]
Without this modification, GLP-1 would be cleared from the body within minutes, making therapeutic use impractical
The American Diabetes Association (ADA) guidelines recognize GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes who require additional glucose-lowering therapy beyond metformin, particularly those with established cardiovascular disease or chronic kidney disease, with preference given to agents with proven cardiovascular benefit
Wichtig: Ozempic ist in Deutschland seit Februar 2018 als Medikament zur Behandlung von Typ-2-Diabetes zugelassen